Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 13/20 | 0.56 |
| ▸ | GRK2 | P25098 | 12/20 | 0.54 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.52 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.44 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL14736164 | 0.98 | ROCK2 (0.55) | ROCK2GRK2PDE10ALOXL2NR1H2 | |
| SCHEMBL4789632 | 0.86 | ROCK2 (0.56) | ROCK2GRK2PDE10ANR1H2NR1H3 | |
| Bromide SCHEMBL4788732 | 0.84 | ROCK2 (0.55) | ROCK2GRK2PDE10ANR1H2NR1H3 | |
| Hydrochloric Acid SCHEMBL4789635 | 0.84 | ROCK2 (0.55) | ROCK2GRK2PDE10ANR1H2NR1H3 | |
| SCHEMBL2228226 | 0.84 | NR1H2 (0.62) | ROCK2GRK2PDE10ALOXL2NR1H2 | |
| Hydrochloric Acid SCHEMBL14736775 | 0.83 | NR1H2 (0.60) | ROCK2GRK2PDE10ALOXL2NR1H2 | |
| SCHEMBL2227964 | 0.81 | RET (0.59) | ROCK2GRK2NR1H2NR1H3 | |
| SCHEMBL2222389 | 0.81 | AOC3 (0.45) | ROCK2PDE10ANR1H2NR1H3 | |
| SCHEMBL14736431 | 0.81 | SMN1; SMN2 (0.55) | PDE10ANR1H2NR1H3KDM4E | |
| SCHEMBL7654725 | 0.80 | ROCK2 (0.53) | ROCK2GRK2PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8772510-B2 | PDE10 modulators | HOFFMANN-LA ROCHE INC. (US) | 2014-07-08 | — | — | US | claimed |
| US-20130059833-A1 | PDE10 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-07 | — | — | US | claimed |
| EP-2753604-B1 | PDE10 MODULATORS | HOFFMANN LA ROCHE (CH) | 2015-08-19 | — | — | EP | disclosed |
| US-8772510-B2 | PDE10 modulators | HOFFMANN-LA ROCHE INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-8637500-B2 | Aminopyridine and carboxypyridine compounds as phosphodiesterase 10 inhibitors | AMGEN INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-8637500-B2 | Aminopyridine and carboxypyridine compounds as phosphodiesterase 10 inhibitors | AMGEN INC. (US) | 2014-01-28 | — | — | US | disclosed |
| EP-2574607-A1 | PDE10 modulators | F. Hoffmann-La Roche AG (CH) | 2013-04-03 | — | — | EP | disclosed |
| WO-2013034506-A1 | PDE10 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-14 | — | — | WO | disclosed |
| US-20130059833-A1 | PDE10 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-07 | — | — | US | disclosed |
| EP-2376455-B1 | AMINOPYRIDINE AND CARBOXYPYRIDINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC (US) | 2012-11-14 | — | — | EP | disclosed |
| WO-2010077992-A1 | AMINOPYRIDINE AND CARBOXYPYRIDINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2010-07-08 | — | — | WO | disclosed |
| US-20100160280-A1 | AMINOPYRIDINE AND CARBOXYPYRIDINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2010-06-24 | — | — | US | disclosed |
| US-20100160280-A1 | AMINOPYRIDINE AND CARBOXYPYRIDINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059833-A1 | PDE10 MODULATORS | PDE10A, PDE5A, PDE2A | ROCK2 76/4885GRK2 288/4885PDE10A 1/4885 |
| US-20100160280-A1 | AMINOPYRIDINE AND CARBOXYPYRIDINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | PDE4A, PDE7A, PDE4D | ROCK2 1333/4885GRK2 1553/4885PDE10A 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.